TY - JOUR
T1 - Posaconazole
T2 - A broad-spectrum triazole antifungal
AU - Torres, Harrys A.
AU - Hachem, Ray Y.
AU - Chemaly, Roy F.
AU - Kontoyiannis, Dimitrios P.
AU - Raad, Issam I.
N1 - Funding Information:
HAT has no conflicts of interest to declare. RYH receives grant support from Schering-Plough. RFC received grant support from Valiant Pharmaceuticals and is a member of the Speakers' Bureau for Wyeth Pharmaceuticals, Elan, and Cubist. DPK received grant support and honoraria from Pfizer, Merck, Fujisawa Healthcare, and Enzon and honoraria from Schering-Plough. IIR receives grant support from, and is a member of the Speakers' Bureau for Merck, Pfizer, and Fujisawa Healthcare, and has received grant support from Schering-Plough, Pharmacia, Cook, Aventis, and Vicuron. His is a co-inventor of medical device technologies licensed to Cook through The University of Texas M D Anderson Cancer Center. DPK and RYH have attended an advisory board meeting on posaconazole in 2005 and received a one-time honorarium.
PY - 2005/12
Y1 - 2005/12
N2 - Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi. Posaconazole is given orally two to four times daily. This triazole is widely distributed in the body, metabolised mainly by the liver, and is well tolerated, even in long-term courses. Adverse events are generally mild and include headache and gastrointestinal complaints. Posaconazole has shown promising clinical efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies - eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis.
AB - Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi. Posaconazole is given orally two to four times daily. This triazole is widely distributed in the body, metabolised mainly by the liver, and is well tolerated, even in long-term courses. Adverse events are generally mild and include headache and gastrointestinal complaints. Posaconazole has shown promising clinical efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies - eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis.
UR - http://www.scopus.com/inward/record.url?scp=28044445699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28044445699&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(05)70297-8
DO - 10.1016/S1473-3099(05)70297-8
M3 - Review article
C2 - 16310149
AN - SCOPUS:28044445699
SN - 1473-3099
VL - 5
SP - 775
EP - 785
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 12
ER -